Inventor
DINGEMANSE JASPER
FR10 patents
⚠️ This page may combine multiple inventors who share the name “DINGEMANSE JASPER”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ACTELION PHARMACEUTICALS LTD
5 patentsUS10220023B2Mar 5, 2019
Dosing regimen for a selective S1P1 receptor agonist
ACTELION PHARMACEUTICALS LTD19 citations92
US10251867B2Apr 9, 2019
Dosing regimen for a selective S1P1 receptor agonist
ACTELION PHARMACEUTICALS LTD2 citations71
US11771683B2Oct 3, 2023
Dosing regimen for a selective S1P1 receptor agonist
ACTELION PHARMACEUTICALS LTD0 citations60
US10857134B2Dec 8, 2020
Dosing regimen for a selective S1P1 receptor agonist
ACTELION PHARMACEUTICALS LTD0 citations50
US10660880B2May 26, 2020
Dosing regimen for a selective S1P1 agonist
ACTELION PHARMACEUTICALS LTD0 citations50
IDORSIA PHARMACEUTICALS LTD
3 patentsUS11390615B2Jul 19, 2022
Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenox
IDORSIA PHARMACEUTICALS LTD1 citations72
US10836754B2Nov 17, 2020
Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
IDORSIA PHARMACEUTICALS LTD1 citations72
US11834443B2Dec 5, 2023
Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
IDORSIA PHARMACEUTICALS LTD0 citations61